←
OncologyEducation29,464 posts
OncologyEducation avatar

OncologyEducation

@OncEd

Evidence-based, educational resources for the oncology community. Authored exclusively by a leading international faculty of oncology.

◷ Joined October 2009▧ 10,161 Photos and videos
OncologyEducation avatar
OncologyEducation@OncEd·Oct 26

Dirk Schadendorf, MD, on the phase 3 STARBOARD study: first-line encorafenib, binimetinib and pembrolizumab vs. placebo and pembrolizumab in BRAF V600–mutant melanoma. #ESMO26 Watch now: bit.ly/4BtJChb

Post attachment
OncologyEducation avatar
OncologyEducation@OncEd·Oct 26

Guillermo De Velasco, MD, PhD, on enfortumab vedotin + pembrolizumab in refractory advanced melanoma (PLUG-IN GEM 2301) and the CD137/PD-L1 bispecific FS222 in PD-1 inhibitor–resistant melanoma. #ESMO26 Watch now: bit.ly/4zdxUWD

Post attachment
OncologyEducation avatar
OncologyEducation@OncEd·Oct 26

Federico Cappuzzo, MD, on a phase 2 trial of OSE2101 plus docetaxel or nivolumab as second-line therapy in metastatic NSCLC after first-line chemo-immunotherapy. #ESMO26 Watch now: bit.ly/47D1tVp

Post attachment
OncologyEducation avatar
OncologyEducation@OncEd·Oct 26

Benjamin Garmezy, MD, on JNJ-6143, a first-in-class oral AR-targeted RIPTAC™, at the optimal dose in metastatic prostate cancer, including high-risk molecular features. #ESMO26 Watch now: bit.ly/4dYJ1dp

Post attachment
OncologyEducation avatar
OncologyEducation@OncEd·Oct 26

Sara Lonardi, MD, on final overall survival from CheckMate 8HW: nivolumab + ipilimumab vs. nivolumab or chemotherapy in MSI-H/dMMR metastatic colorectal cancer. #ESMO26 Watch now: bit.ly/4zd51ty

Post attachment
OncologyEducation avatar
OncologyEducation@OncEd·Oct 26

Andrea Cercek, MD, on first results from the global registrational AZUR-1 trial: clinical complete response with dostarlimab alone in dMMR/MSI-H locally advanced rectal cancer. #ESMO26 Watch now: bit.ly/4eOJDCv

Post attachment
OncologyEducation avatar
OncologyEducation@OncEd·Oct 26

Sanjiv Gangaram-Panday, PhD, on long-term results from the SANO trial: active surveillance vs. standard surgery after neoadjuvant chemoradiotherapy for esophageal cancer. #ESMO26 Watch now: bit.ly/4z9IkWW

Post attachment
OncologyEducation avatar
OncologyEducation@OncEd·Oct 26

Hong Jae Chon, MD, PhD, on first phase 1 dose-escalation and dose-optimization data for BGB-B2033, a GPC3 × 4-1BB bispecific antibody, in advanced hepatocellular carcinoma. #ESMO26 Watch now: bit.ly/4yKmqc1

Post attachment
OncologyEducation avatar
OncologyEducation@OncEd·Oct 26

Carlos Barcenas, MD, MSc, on pre-interim results from B-STRONGER-I: ultrasensitive ctDNA monitoring during neoadjuvant treatment in early-stage triple-negative breast cancer. #ESMO26 Watch now: bit.ly/4Bk5ag6

Post attachment
OncologyEducation avatar
OncologyEducation@OncEd·Oct 26

Kamran Ahmed, MD, on the phase 2 INSPIRE-LM study: radiation therapy followed by intrathecal trastuzumab/pertuzumab for HER2+ breast cancer leptomeningeal metastasis. #ESMO26 Watch now: bit.ly/3UjVOAs

Post attachment